Last updated: 2026-10-05 08:21:00. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Alzamend Neuro, Inc. (ALZN) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $1.38, with a market capitalization of $6.61M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.84 to $2.68. This page covers its latest market performance, valuation, price trends and company information.
$6.61M | |
$1.36 | |
$45,292.50 | |
$0.84 | |
$1.37 | |
72.00 | |
92.08K | |
-- | |
$2.68 | |
$0.84 | |
-- | |
-- |
Alzamend Neuro, Inc. (ALZN) is trading at $1.38 in pre-market trading as of 2026-10-05 08:17:00, up 0.66% ($0.01) from the previous close of $1.37
Pre-market trading shows how investors are pricing ALZN before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, Alzamend Neuro, Inc. (ALZN) moved from $1.82 to $1.38, representing a decline of 24.23% ($0.44).
The stock traded between $1.20 and $1.93 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 102.31 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 29.3%
ALZN is currently trading at $1.38, placing it 29.3% of the way from its 52-week low of $0.84 to its 52-week high of $2.68. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's disease. The Company has two therapeutic drug candidates, AL001 and ALZN002. Its pipeline consists of AL001, a patented ionic cocrystal technology delivering lithium through a therapeutic combination of lithium, proline and salicylate; and ALZN002, a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's disease.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 6 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Alzamend Neuro, Inc. (ALZN) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.